MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 16, 2007; DOI: 10.1124/mol.107.039511


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.039511v1
73/1/147    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Desmarais, S.
Right arrow Articles by Percival, M D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Desmarais, S.
Right arrow Articles by Percival, M D.


Received for publication June 29, 2007.
Revised October 12, 2007.
Accepted for publication October 12, 2007.

Effect of cathepsin K inhibitor basicity on in vivo off-target activities

Sylvie Desmarais 1, W Cameron Black 1, Renata Oballa 1, Sonia Lamontagne 1, Denis Riendeau 1, Paul Tawa 1, Le Thi Duong 2, Maureen Pickarski 2, M David Percival 1*

1 Merck Frosst Canada 2 Merck Research Laboratories, USA

* Address correspondence to: E-mail: dave_percival{at}merck.com

Abstract

Cathepsin K is a lysosomal cysteine protease that is a pharmacological target for the treatment of osteoporosis. Previous studies showed that basic, lipophilic cathepsin K inhibitors are lysosomotropic and have greater activities in cell-based assays against cathepsin K, as well as the physiologically important lysosomal cysteine cathepsins B, L and S than expected on the basis of their potencies against these isolated enzymes. Chronic administration of the basic cathepsin K inhibitors L-006235 and balicatib to rats at a supratherapeutic dose of 500 mg/kg/d for four weeks resulted in increased tissue protein levels of cathepsin B and L, but no effect on cathepsin B and L message. This is attributed to the inhibitor engagement of these off-target enzymes and their stabilisation to proteolytic degradation. No such increase in these tissue cathepsins was detected at the same dose of L-873724, a potent non-basic cathepsin K inhibitor with a similar off-target profile, although all three inhibitors provided similar plasma exposures. Using an activity-based probe [125I]-BIL-DMK, in vivo inhibition of cathepsins B, L and S was detected in tissues of mice given a single oral dose of L-006235 and balicatib, but not in mice given L-873724. In each case, similar tissue levels were achieved by all three compounds, thereby demonstrating the in vivo cathepsin selectivity of L-873724. In conclusion, basic cathepsin K inhibitors demonstrate increased off-target cysteine cathepsin activities than their non-basic analogues and potentially have a greater risk of adverse effects associated with inhibition of these cathepsins.


Key words: Structure-activity relationships and modeling, Protein targets


This article has been cited by other articles:


Home page
IBMS BoneKEyHome page
S. B. Rodan and L. T. Duong
Cathepsin K - A New Molecular Target for Osteoporosis
IBMS BoneKEy, January 1, 2008; 5(1): 16 - 24.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics